Market situation of anti pancreatic cancer drugs

As we all know, pancreatic cancer is one of the most difficult malignant tumors in clinic It is reported that newly diagnosed pancreatic cancer accounts for 2% of new cancers in the United States every year The clinical results show that the early detection rate of pancreatic cancer is very low, and the surgical treatment of pancreatic cancer is more difficult than other malignant tumors, and the prognosis is not optimistic Only 25% of patients can survive with the help of gemcitabine, a standard chemotherapy drug Currently, the main chemotherapy drugs approved by FDA for the treatment of pancreatic cancer are gemcitabine, a standard treatment drug, and erlotinib On September 9, 2013, the FDA approved gemcitabine plus Abraxane (albumin binding paclitaxel for injection) for the first-line treatment of metastatic pancreatic cancer The antitumor drugs capecitabine, sunitinib, everolimus, sorafenib and acetinib all have therapeutic effects on pancreatic cancer Among them, sunitinib and everolimus are used in the treatment of functional pancreatic neuroendocrine tumor (pnt) The traditional combination therapy of fluorouracil and calcium folinate is still a cost-effective treatment in developing countries In 2012, the global pancreatic cancer treatment market has reached US $7.662 billion, an increase of 7.51% over the previous year Statistics show that the incidence rate of cancer has increased by 80% in the past 30 years Cancer has become the first leading cause of death in China Compared with western countries, the overall incidence rate of pancreatic cancer is slightly lower in China, but the population base is large There is a certain gap between the level of treatment and chemotherapy In 2012, the total market scale of anti-tumor, immune enhancement and support drugs in sample hospitals of 16 key cities in China reached 15.8 billion yuan, an increase of 17.75% over the previous year Due to the multi-target characteristics of anti-tumor drug indications, the market of chemotherapy drugs for pancreatic cancer has reached 1.5 billion yuan, accounting for 10% of the hospital tumor chemotherapy market, an increase of 12.69% over the previous year Gemcitabine is a new nucleoside derivative of cytosine, which came out in the 20th century After the successful development of Eli Lilly, it was first listed in Sweden, the Netherlands, Finland and South Africa in 1995 On May 15, 1996, it was approved by FDA for the treatment of pancreatic cancer and non-small cell lung cancer The injection drug was sold in the United States under the trade name Gemzar The FDA Cancer Drug Advisory Committee recommends its use in the treatment of advanced and metastatic pancreatic cancer After years of market cultivation by the original drug manufacturers, Gemzar started rapidly and became a heavy bomb drug in 2008 But after the expiration of patents and the listing of generic drugs, the market inevitably began to decline In 2011, Lilly's Gemzar sales fell to $452 million, down 60.67% from the previous year, according to IMS After gemcitabine was introduced into China in 1999, the clinical use of pancreatic cancer in China has been greatly improved Domestic gemcitabine was listed earlier, and gemcitabine (zefei) of Jiangsu Haosen Pharmaceutical Co., Ltd and Yujie of Harbin Yuheng Pharmaceutical Co., Ltd were first approved After the expiration of its patent protection, a number of domestic enterprises were approved to produce gemcitabine On June 26, 2013, a new batch of gemcitabine of Huangshi Feiyun pharmaceutical was approved At present, 13 domestic gemcitabine have been approved for listing Gemcitabine has entered the 2009 National Medical Insurance catalogue, which promotes the market development In 2012, the amount of gemcitabine used in the sample hospitals of 16 key cities in China was nearly 400 million yuan, accounting for a quarter of the pancreatic cancer drug treatment market, an increase of 9.12% over the previous year It is estimated that the domestic market of gemcitabine has reached 2 billion yuan, ranking the third among anti-tumor and anti metabolism drugs Erlotinib, a tyrosine kinase inhibitor, is a small molecule targeted anticancer drug jointly developed by Roche of Switzerland, Genentech of the United States and OSI pharmaceutical company Its trade name is Tarceva Erlotinib has unique clinical location, target and mechanism in many Tinian drugs In September 2002, it was awarded by FDA as the second-line or third-line treatment drug fast track approval qualification, which is applicable to patients who have received standard therapy for advanced metastatic pancreatic cancer In addition, erlotinib also conducted clinical trials for breast, ovarian, colorectal and brain cancers In September 2005, erlotinib was first approved in the European Union for the second and third line treatment of non-small cell lung cancer According to the clinical application data in recent years, the combination of erlotinib and gemcitabine can improve the overall survival rate of patients with pancreatic cancer by 23.5%, showing the positive role of targeted anti-tumor drugs, thus promoting the growth of erlotinib market Especially after 2010, Roche of Switzerland, Genentech of the United States, OSI pharmaceutical company, Japanese and foreign pharmaceutical companies, and Astaire jointly developed the erlotini market, which promoted the development of the market According to the data, in 2012, the global sales of erlotini reached nearly $2 billion, an increase of 5.05% over the previous year In October 2007, Roche's erlotinib oral tablets were approved for registration in China and listed under the trade name Tarceva At present, the domestic market of erlotinib is mainly troika of Roche in Switzerland, and the domestic drugs are still under development In 2012, the amount of erlotinib used in sample hospitals in 16 key cities in China was more than 150 million yuan, an increase of 5% over the previous year In the past two years, TiNi drugs have become a hot spot in the field of anti-tumor Global new drug research and development and domestic generic drug development have targeted this field, and its market prospect is widely optimistic The target action point of the drug and the market strategy, positioning and promotion ability of the enterprise will play an absolute role in promoting the development of its treatment market With the upgrading of TiNi products, there will be fierce competition among similar products Capecitabine is the first oral fluoropyrimidine carbamate antitumor drug on the market It is developed by Roche company and the trade name is "Xeloda" In April 1998, it was approved to be listed in the United States, and then successively listed in Switzerland and other countries In November 1999, capecitabine began to conduct clinical trials in China and was listed in China under the trade name of "Xeloda" Capecitabine is a drug for colorectal cancer and metastatic breast cancer It is also used for the treatment of gastric cancer and pancreatic cancer In addition, capecitabine is a promising combination chemotherapy drug for solid tumors such as non-small cell lung cancer, ovarian cancer, bladder cancer, prostate cancer, leukemia and lymphoma In 2012, the global sales volume of Xeloda was 1.523 billion Swiss francs, an increase of 12.48% over the previous year Capecitabine has entered the 2009 National Medical Insurance catalogue From the perspective of patients' payment ability, it has a high cost performance ratio Moreover, because of the convenience of oral preparation, it also has a certain advantage in pharmacoeconomics, thus promoting the market development In 2012, the amount of capecitabine used in the sample hospitals of 16 key cities in China was more than 465 million yuan, an increase of 5.40% over the previous year At present, Xeloda is still the only brand in the domestic capecitabine preparation market, which is exclusively owned by Roche and its joint venture Shanghai Roche With the expiration of capecitabine patent, on September 16, 2013, FDA approved the first generic drug of capecitabine oral chemotherapy of TIWA Capecitabine's patent in China expired on December 17, 2013, and the rush for imitation has been on the rise since 2011 According to the website of the State Food and drug administration, Sinopharm holding subsidiary Yixin Pharmaceutical Co., Ltd is developing six kinds of generic drug capecitabine tablets and applying for production As of August 13, nearly 20 domestic manufacturers have applied for capecitabine It is reported that capecitabine APIs of Jiangsu Hengrui Pharmaceutical Co., Ltd., Qilu Tianhe Huishi Pharmaceutical Co., Ltd and Lianyungang Runzhong Pharmaceutical Co., Ltd have been approved for production The imitated capecitabine preparations of Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Chongqing qingyutang Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Beijing Zhaoyan new drug research center, etc have been in clinical trials or production reports, after the expiry of the original research drug patent It will be approved With the opening of the competition of domestic capecitabine imitation, in the future, it will be the multiple benefits of producers, social insurance system and patients